PARP1 and Alzheimer disease: In preclinical studies, PARP1 inhibitors have been reported to have therapeutic potential as treatment for cardiovascular diseases and Alzheimer’s disease, and as chemotherapeutic agents that may prevent unwanted necrosis23, 80.